Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | INVICTUS and INTRIGUE: investigating ripretinib in patients with advanced GIST

Robin Jones, MD, The Royal Marsden Hospital, London, UK, provides an overview of the Phase III INVICTUS (NCT03353753) trial, investigating the switch-control kinase inhibitor, ripretinib, in patients with advanced gastrointestinal stromal tumors (GIST) who had progressed on at least imatinib, sunitinib and regorafenib. The primary endpoint of progression-free survival (PFS) was met, with patients receiving ripretinib achieving a 6.3 month median PFS, versus a 1 month median PFS for patients receiving placebo. The results lead to the FDA approval of ripretinib in the fourth-line setting for the treatment of advanced GIST. The Phase III INTRIGUE (NCT03673501) clinical trial investigated ripretinib versus sunitinib in patients with advanced GIST previously treated with imatinib, demonstrating no significant difference between ripretinib and sunitinib, although ripretnib showed a superior safety profile.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.